Literature DB >> 7164466

[A case of chronic pulmonary hypertension after fenfluramine intake].

G Gaul, G Blazek, E Deutsch, H Heeger.   

Abstract

A case of primary vascular pulmonary hypertension (PVPH) in a 53-year old woman (160 cm, 90 kg) is reported. She first complained of symptoms of breathlessness on exertion 2-3 months after completion of three courses of fenfluramine (Ponderax). The courses began in October 1977 and ended in May 1978. Despite persisting symptoms no relevant clinical findings were obtained. The patient was admitted to this hospital after complaining of short syncopal attacks on exertion, in November 1981. Typical signs of PVPH were now demonstrable, with a resting pulmonary pressure of 98/45 mm Hg. Clinical findings showed a similarity to those obtained in patients suffering from aminorex-induced PVPH, although fenfluramine shows some biological differences to aminorex. A causality between the development of PVPH and fenfluramine intake is probable on the basis of the patient's history, but it cannot be proven.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7164466

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  7 in total

1.  Fenfluramine--induced irreversible pulmonary hypertension.

Authors:  I Fotiadis; T Apostolou; A Koukoulas; N Michelacakis; D Kremastinos
Journal:  Postgrad Med J       Date:  1991-08       Impact factor: 2.401

2.  Irreversible pulmonary hypertension after treatment with fenfluramine.

Authors:  J McMurray; P Bloomfield; H C Miller
Journal:  Br Med J (Clin Res Ed)       Date:  1986-01-25

3.  Irreversible pulmonary hypertension after treatment with fenfluramine.

Authors:  K Watters; A Le Ridant
Journal:  Br Med J (Clin Res Ed)       Date:  1986-04-26

4.  Irreversible pulmonary hypertension after treatment with fenfluramine.

Authors:  J McMurray; P Bloomfield; H C Miller
Journal:  Br Med J (Clin Res Ed)       Date:  1986-07-05

Review 5.  Dexfenfluramine. An updated review of its therapeutic use in the management of obesity.

Authors:  R Davis; D Faulds
Journal:  Drugs       Date:  1996-11       Impact factor: 9.546

6.  Appetite suppressants and primary pulmonary hypertension in the United Kingdom.

Authors:  S H Thomas; A Y Butt; P A Corris; J J Egan; T W Higenbottam; B P Madden; P C Waller
Journal:  Br Heart J       Date:  1995-12

7.  Primary pulmonary hypertension and fenfluramine use.

Authors:  F Brenot; P Herve; P Petitpretz; F Parent; P Duroux; G Simonneau
Journal:  Br Heart J       Date:  1993-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.